Aptus Pharma Gets BSE Nod for ₹44.78 Crore Share Issue

Aptus Pharma Limited received BSE Limited's in-principle approval on October 30, 2026, to issue 15,99,270 equity shares at ₹280 each, a proposed capital raise of about ₹44.78 crore for its manufacturing expansion plans. The board was scheduled to consider the allotment on November 12, 2026.

What approval has Aptus Pharma received for its share issue?

Aptus Pharma received in-principle approval from BSE on October 30 for a preferential issue of 15,99,270 equity shares. The approved issue price is not less than ₹280 per share, including a premium of ₹270 over the ₹10 face value of each equity share. At the stated share count and price, the issue could raise approximately ₹44.78 crore.

The approval was granted under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is an exchange-level clearance that allows the company to proceed with the proposed issuance, subject to compliance with applicable conditions and listing requirements.

BSE specifically stated that its in-principle approval is not final listing approval. Following allotment, Aptus Pharma is required to submit a listing application, together with applicable fees, without delay and within 20 days from the allotment date.

The company said the proposed shares are intended for promoters and non-promoters. The disclosures provided do not identify the individual allottees or the final shareholding pattern after the proposed allotment.

Why is the board meeting on November 12 important?

Aptus Pharma informed BSE on November 6 that its board of directors would meet on November 12 to consider and approve the allotment of equity shares on a preferential basis. This meeting is the next disclosed corporate step after the exchange's in-principle approval.

The proposal had already received shareholder consent at the company's 16th annual general meeting on September 14, 2026. The special resolution for preferential allotment was passed with 1,39,38,000 votes in favour and no votes against.

Promoter and promoter-group shareholders held 1,25,00,000 shares and voted fully in favour of the resolution. Public non-institutional shareholders held 14,38,000 shares and also voted unanimously in favour. No institutional public shareholders participated in the voting process, according to the disclosed voting details.

The board had earlier approved a proposal, disclosed as up to 16,02,870 equity shares at ₹280 apiece, aggregating up to ₹44.88 crore. The later BSE approval covers 15,99,270 shares. The company must complete the allotment process and required filings before the new shares can be listed and admitted for trading.

How will Aptus Pharma use the proposed capital?

Aptus Pharma has linked the preferential issue to a manufacturing expansion project initially estimated at ₹35 crore. The company indicated that around ₹25 crore of the capital expenditure is expected to be funded through the preferential issue.

The remaining funding required for the project, as well as any future funding needs, will be arranged as needed during execution. The available disclosures do not specify the project location, timeline, production capacity, or the precise allocation of proceeds beyond the stated manufacturing expansion purpose.

The proposed issue size is higher than the approximately ₹25 crore indicated for this capital expenditure funding component. This indicates that the announced fundraising capacity can support the stated expansion requirement, although the company has not given a detailed use-of-proceeds break-up in the information provided.

For investors, the distinction between the estimated project cost, the funding earmarked from the preferential issue, and the total approved issue amount is relevant. The company has provided figures for each, but has not disclosed a final project financing schedule or a date for completing the expansion.

What does the preferential issue mean for shareholders?

Aptus Pharma's preferential issue would increase the number of equity shares outstanding once the shares are allotted. That can dilute the ownership percentage of existing shareholders who do not receive shares in the issue, depending on the final allotment and the company's post-issue capital structure.

The issue price of ₹280 per share is the disclosed transaction price for the identified proposed allottees. The provided announcements do not state Aptus Pharma's market price at the time of approval, so no comparison between the issue price and the prevailing share price can be made from the available information.

The proposal includes both promoter and non-promoter participants. Promoter participation can provide additional capital from existing controlling shareholders, while allotment to non-promoters can alter the ownership mix. However, the available disclosures do not quantify how many shares will be allotted to each category.

The immediate compliance milestone is the board's consideration of allotment. Once shares are allotted, Aptus Pharma must file for listing within the prescribed 20-day period. Until listing approval is separately received, BSE's October 30 clearance should not be treated as approval for the new shares to trade.

Conclusion

Aptus Pharma has moved through two key steps for its preferential issue: unanimous shareholder approval in September and BSE's in-principle approval in October. The exchange-approved proposal covers 15,99,270 shares at ₹280 each, representing potential proceeds of about ₹44.78 crore, while the company has linked approximately ₹25 crore of planned funding to its manufacturing expansion project.

The next disclosed event is the November 12 board meeting to consider and approve the share allotment. Investors should watch for the board outcome, the number of shares actually allotted, details of the allottees, any post-allotment shareholding disclosure, and the subsequent listing application required within 20 days of allotment.